Oral Mucositis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Oral Mucositis (OM), also called stomatitis, is the most common, debilitating complication of cancer chemotherapy and radiotherapy, characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment. Typical manifestations of Oral Mucositis are varying degrees of erythema, atrophy, ulceration, and mucosa swelling. It has a significant negative impact on patients’ quality of life (QOL). Potential complications of OM include pain, increased the risk of local and systemic infections, bleeding, insufficient food intake, delays in the administration of radiotherapy and or chemotherapy, a dose reduction of the chemotherapy drugs, increased the length of hospital stays, associated economic burdens and in some cases life-threatening infections (septicemia in neutropenic instances). Mucositis is one of the most generally reported toxicities of mTOR inhibitors, and in some studies, it was the dose-limiting toxicity. Oral toxicities with other targeted agents, such as kinase inhibitors and monoclonal antibodies, are less common. Yet studies have shown a significant incidence of all-grade mucositis with bevacizumab, erlotinib, sorafenib, and sunitinib.

 

The incidence of oral toxicity associated with targeted agents has been shown to increase as the dose increases. The incidence of Oral Mucositis (OM) ranges from 590 to 650 cases per 100,000 population in the USA.

 

The competitive landscape of Oral Mucositis includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Oral Mucositis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Oral Mucositis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Oral Mucositis – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Melatonin oral gel          Spherium Biomed          Phase 2

2          Clonidine HCl Mucoadhesive Buccal Tablet        Monopar Therapeutics     Phase 3

3          Bocaliner          E2Bio Life Sciences, LLC           Phase 2

4          RRx-001           EpicentRx, Inc.  Phase 2

5          IZN-6N4            Izun Pharma Ltd            Phase 2

6          EISO mouth rinse          Santalis Pharmaceuticals, Inc.   Phase 2

7          SGX942            Soligenix           Phase 3

8          GC4419            Galera Therapeutics, Inc.           Phase 3

9          Clonidine Lauriad®        Onxeo  Phase 2

10        velafermin         Celldex Therapeutics     Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypoglycemia and severe
Read more